1. Report Overview

1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview

1.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. Alzheimer’s Disease: An Introduction

2.1 Neurodegenerative Diseases

2.1.1 What is Alzheimer’s Disease?

2.1.2 What Causes Alzheimer’s Disease?

2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?

2.1.3 Management of Alzheimer’s Disease

2.1.4 The Socio-Economic Impact of Alzheimer’s Disease

2.1.5 Diagnosis of Alzheimer’s Disease

3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2028

3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2017

3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition

3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses

3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry

3.3 Drivers and Restraints

3.4 Shift in Focus to Early Disease Stages

4. The Alzheimer’s Disease Drugs Market, 2017-2028

4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease

4.2 The Alzheimer’s Disease Drugs Market, 2017

4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2017-2028

4.4 The Alzheimer’s Disease Drugs Market Forecast 2017-2028

4.5 Namenda – Forest Laboratories, Subsidiary of Allergan

4.5.1 Namenda Sales Forecast, 2017-2028

4.6 Aricept

4.6.1 Aricept Sales Forecast, 2017-2028

4.7 Exelon

4.7.1 Exelon Sales Forecast, 2017-2028

4.8 Alzheimer’s Disease Drugs Pipeline, 2017

4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer’s Drugs and EMA published new draft guidance for AD treatments

4.8.2 Will Novel Drug Development Strategies Prove Successful?

4.8.3 Solanezumab (Eli Lilly)

4.8.3.1 Solanezumab Sales Forecast 2017-2028

4.8.4 Gantenerumab (Roche)

4.8.4.1 Gantenerumab Pipeline Forecast, 2017-2028

4.8.5 Verubecestat MK-8931 (Merck)

4.8.5.1 Verubecestat MK-8931 Pipeline Forecast, 2017-2028

4.8.6 Idalopirdine Lu AE58054 (Lundbeck)

4.8.7 Azeliragon TTP488 (TransTechPharma)

4.8.8 LMTX (TauRx)

4.8.9 Encenicline EVP-6124 (Forum Pharmaceuticals)

4.8.10 Axona (Accera)

4.8.11 AD-4833 (Takeda Pharmaceuticals)

4.8.12 Intepirdine RVT-101 (Axovant Sciences Ltd)

4.9 Deep Brain Stimulation (Functional Neuromodulation)

4.10 Recent Research on Alzheimer’s Disease

5. Leading Companies in the Alzheimer’s Disease Drugs Market, 2017

5.1 Pfizer, Inc.

5.1.1 Sales and Recent Performance Analysis, 2017

5.1.2 Pfizer: Aricept

5.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates

5.2 Eisai

5.2.1 Sales and Recent Performance Analysis, 2017

5.2.2 Eisai: Aricept

5.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates

5.2.4 Collaboration with Biogen

5.2.5 Partnership with GE Healthcare for Diagnostic Development

5.3 Forest Laboratories (Acquired by Allergan)

5.3.1 Acquisition by Allergan

5.3.2 Forest: Namenda

5.3.3 Namenda’s Sales and Recent Performance Analysis, 2017

5.4 Lundbeck A/S

5.4.1 Sales and Recent Performance Analysis, 2017

5.4.2 Lundbeck: R&D Capabilities

5.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline

5.4.4 Lundbeck: Ebixa

5.5 Daiichi Sankyo

5.5.1 Financial Sales and Recent Performance, 2017

5.5.2 Daiichi Sankyo: Memary

5.6 Novartis AG

5.6.1 Sales and Recent Performance Analysis

5.6.2 Novartis: Exelon

5.6.3 eHealth Programme Delivering Innovation

5.6.4 Novartis: Alzheimer’s Disease Drug Pipeline

5.7 TauRx

5.7.1 Partnership with Bayer Schering Pharma AG

5.8 vTv Therapeutics

5.8.1 TTP Translational Technology

5.8.2 vTv Therapeutics: Alzheimer’s Disease Pipeline Portfolio

6. The Alzheimer’s Disease Diagnostics Market, 2017-2028

6.1 There is Still a Strong Market Need for Effective Diagnosis

6.2 The Alzheimer’s Disease Diagnostics Market, 2017

6.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2017-2028

6.4 The Alzheimer’s Diagnostics Market, 2017-2028

6.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease

6.6 Biomarkers for Alzheimer’s Disease

6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies

6.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies

6.7.1 Structural Imaging

6.7.2 Functional Imaging

6.7.3 Molecular Imaging Technologies

6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)

6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)

6.7.3.3 Flutemetamol (GE Healthcare)

6.7.3.4 Florbetaben (Piramal Imaging)

6.8 Other Alzheimer’s Diagnostics in Development

6.8.1 CSF Proteins

6.8.2 Blood Based Biomarkers for Alzheimer’s Disease

6.8.3 Genetic Risk Profiling

6.8.4 Eye Tests

6.8.5 Nanoparticles

6.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2017

6.9.1 Eli Lilly

6.9.1.1 Recent Performance and Sales Analysis, 2017

6.9.1.2 Alzheimer’s Disease Research Effort

6.9.1.3 Solanezumab

6.9.1.4 Lanabecestat

6.9.1.5 Amyvid (Florbetapir F18)

6.9.1.6 Amyvid Receives Marketing Authorization from the European Commission

6.9.1.7 Flortaucipir F-18

6.9.1.8 LY3002813: Phase I

6.9.2 Amarantus BioScience Holdings, Inc.

6.9.2.1 Recent Performance and Sales Analysis, 2014

6.9.2.2 Avant Diagnostics Inc acquire Amarantus Diagnostics Inc

6.9.2.3 LymPro

6.9.2.4 Intellectual Property Acquisitions

6.9.3 Piramal Enterprises

6.9.3.1 Piramal Imaging SA

6.9.3.2 FDA and EMA Approval of Florbetaben

6.9.3.3 Manufacturing and Distribution Agreements

6.9.4 GE Healthcare

6.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field

6.9.4.2 Regulatory Approval of Vizamyl - Flutemetamol

6.9.4.3 Licensing Agreements for Flutemetamol

6.9.5 Navidea

6.9.5.1 NAV4694 (Fluorine-18)

6.9.5.2 Collaboration Agreements

6.9.5.3 NAV4694 Clinical Development

6.9.6 DiaGenic

7. The Leading National Markets, 2017-2028

7.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2017

7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market

7.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2017-2028

7.3 Changing Market Shares of Leading National Markets 2017-2028

7.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2017-2028

7.4.1 One in Nine Over the Age of 65 has AD in the US

7.4.2 The US Will Remain the Largest Market Over the Forecast Period

7.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2017-2028

7.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.5.4 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.5.5 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

7.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2017-2028

8. Qualitative Analysis of the Alzheimer’s Disease: Therapeutics and Diagnostics Market, 2017-2028

8.1 SWOT Analysis

8.2 Strengths

8.2.1 Alzheimer’s Disease is a High-Profile Disease

8.2.2 Expanding Patient Population

8.2.3 Strong R&D Pipeline in Both Sectors of the Market

8.3 Weaknesses

8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease

8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials

8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market

8.4. Opportunities

8.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development

8.4.2 Neurodegenerative Diseases Have Strong R&D

8.4.3 Emerging Markets Will Help Drive the Market

8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration

8.5 Threats

8.5.1 Patent Expiries Will Lead to Further Generic Competition

8.5.2 New AD Therapies Face Political, Commercial and Social Pressures

8.6 Porter’s Five Force Analysis

8.6.1 Rivalry Among Competitors

8.6.2 Threats of New Entrants

8.6.3 Powers of Suppliers

8.6.4 Bargaining Power of Buyers

8.6.5 Threat of Substitutes

9. Research Interviews

9.1 Interview with David Hung, M.D., CEO of Axovant Sciences Inc.

9.1.1 Axovant Sciences Inc.

9.1.2 Intepirdine for The Treatment of Alzheimer’s Disease

9.1.3 Intepirdine for The Treatment of Lewy Body Dementia

9.1.4 Candidates in Phase 1 for Alzheimer’s Disease

9.2 Interview with Gill Farrar, PhD, Scientific Director, PET Neurology – Medical Affairs at GE Healthcare

9.2.1 GE Healthcare

9.2.2 Progress in Alzheimer’s Research

9.2.3 Global Alzheimer’s Diagnostics Market

9.2.4 Broadening Vizamyl’s Use

9.2.5 New EMA Guidelines to Include Early Disease Stages

9.3 Interview with Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.

9.3.1 Eli Lilly and Co.

9.3.2 Global Alzheimer’s Disease Therapeutics market

9.3.3 Lilly’s Pipeline, Drugs and Diagnostics for Alzheimer’s Disease

9.3.4 Challenges in Developing Biomarkers

10. Conclusion

10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs

10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market

10.3 Demographics Will Help Drive the Market Over the Forecast Period

10.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2016 to 2027

10.5 Research for Alzheimer’s Happening across the World

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

Table of Tables

Table 2.1 Leading Sectors in The Neurodegenerative Disease Market, 2017

Table 2.2 Imaging Technologies Used in Alzheimer’s Research, 2017

Table 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2017

Table 3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2017-2028

Table 3.3 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2018

Table 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2017

Table 4.2 Market Shares (%) of the Leading Alzheimer’s Drugs, 2017, 2022, 2028

Table 4.3 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.4 Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.5 Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.6 Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.7 Alzheimer’s Disease Drugs in the Pipeline Phase 3, 2017

Table 4.8 Disease Drugs in the Pipeline Phase 2, 2017

Table 4.9 Alzheimer’s Disease Drugs in the Pipeline Phase 1, 2017

Table 4.10 Solanezumab Clinical Trial Results

Table 4.11 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.12 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.13 Verubecestat Clinical Trial Results

Table 4.14 Merck: Verubecestat MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 4.15 Idalopirdine Clinical Trial Results results

Table 5.1 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2017

Table 5.2 Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 5.3 Pfizer: Alzheimer’s Disease Drug Pipeline, 2017

Table 5.4 Eisai: Aricept Historical Regional Sales ($m), AGR (%), 2013

Table 5.5 Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 5.6 Biogen: Alzheimer’s Disease Drugs Pipeline, 2017

Table 5.7 Forest: Namenda’s Historical Revenues ($bn) and AGR (%), 2010-2015

Table 5.8 Allergan: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 5.9 Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2016

Table 5.10 Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2017

Table 5.11 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 5.12 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2017-2028

Table 5.13 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2016

Table 5.14 vTv Therapeutics: Alzheimer’s Disease Drugs Pipeline, 2018

Table 6.1 The Alzheimer’s Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2017

Table 6.2 Market Shares (%) of the Leading Alzheimer’s Diagnostics Markets, 2017, 2022 and 2028

Table 6.3 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2017-2028

Table 6.4 Key Alzheimer’s Diagnostic Tests in Development, 2017

Table 6.5 Eli Lilly Pipeline Including Drugs and Diagnostics for Alzheimer’s Disease

Table 6.6 DiaGenic: Alzheimer’s Disease Diagnostics Pipeline, 2016

Table 7.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2017

Table 7.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2017-2028

Table 7.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2017-2022, 2022-2028, 2017-2028

Table 7.4 Market Shares (%) of the Leading Regional Alzheimer’s Disease Therapeutics and Diagnostics Markets, 2017, 2022 and 2028

Table 7.5 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.6 The European Alzheimer’s Therapeutics and Diagnostics Market: Revenue ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2017

Table 7.7 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.8 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.9 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2017-2028

Table 7.10 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.11 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.12 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.13 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.14 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.15 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.16 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.17 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.18 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 7.19 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 8.1 SWOT Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2017

Table 10.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2017, 2022 and 2028 and CAGR (%) 2017-2022 and 2022-2028 by Region

Table 10.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2017, 2022 and 2028

Table of Figures

Figure 1.1 Alzheimer’s Disease Therapeutics and Diagnostics: Overview of Submarkets and Segments

Figure 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2017

Figure 3.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2017

Figure 3.3 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 3.4 Current Stage in Research and Development for Alzheimer’s Disease

Figure 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2017

Figure 4.2 The Alzheimer’s Disease Drugs Market: Market Shares (%) by Leading Drugs, 2017

Figure 4.3 The Alzheimer’s Therapeutics Market: Market Shares (%) byDrug, 2022

Figure 4.4 The Alzheimer’s Therapeutics Market: Market Shares (%) by Drug, 2028

Figure 4.5 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 4.6 Namenda: Sales Forecast ($bn), 2017-2028

Figure 4.7 Aricept: Sales Forecast ($bn), 2017-2028

Figure 4.8 Exelon: Sales Forecast ($bn), 2017-2028

Figure 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), 2017-2028

Figure 4.10 Roche: Gantenerumab Sales Forecast ($bn), 2017-2028

Figure 4.11 Merck: MK-8931 Sales Forecast ($bn), 2017-2028

Figure 5.1 Pfizer: Historical Revenues ($bn), 2012-2017

Figure 5.2 Pfizer: Revenues ($bn) by Sector, 2017

Figure 5.3 Pfizer: Revenue Shares (%) by Sector, 2017

Figure 5.4 Pfizer: Aricept Sales Forecast ($bn), 2017-2028

Figure 5.5 Pfizer: Historical R&D Expenditure ($bn), 2012-2017

Figure 5.6 Eisai: Aricept Historical Revenue ($bn) 2013-2016

Figure 5.7 Eisai: Aricept Sales Forecast ($bn), 2017-2028

Figure 5.8 Eisai: Historical R&D Expenditure ($bn), 2013-2015

Figure 5.9 Forest: Namenda’s Historical Revenue ($bn), 2010-2015

Figure 5.10 Allergan: Namenda Sales Forecast ($bn), 2017-2028

Figure 5.11 Lundbeck: Revenue Share (%) by Region, 2016

Figure 5.12 Lundbeck: Revenue Share ($bn) by Region, 2016

Figure 5.13 Lundbeck: R&D Expenditure ($bn), 2015-2016

Figure 5.14 Ebixa: Revenue ($bn) by Region, 2016

Figure 5.15 Ebixa: Revenue Shares (%) by Region, 2016

Figure 5.16 Ebixa: Sales Forecast ($bn), 2017-2028

Figure 5.17 Daiichi Sankyo: Historical Revenue ($bn), 2012-2015

Figure 5.18 Daiichi Sankyo: Memary Historical Revenue ($bn), 2013-2015

Figure 5.19 Daiichi Sankyo: Memary Sales Forecast ($bn), 2017-2028

Figure 5.20 Novartis: Historical Revenues ($bn), 2012-2016

Figure 5.21 Novartis: Revenues ($bn) by Segment, 2016

Figure 5.22 Novartis: Revenue Shares (%) by Segment, 2016

Figure 5.23 Exelon: Historical Revenue Shares (%) by Region, 2016

Figure 6.1 The Alzheimer’s Disease Diagnostics Market:

Revenues ($bn) by Segment, 2017

Figure 6.2 The Alzheimer’s Disease Diagnostics Market:

Market Shares (%) by Segment, 2017

Figure 6.3 The Alzheimer’s Diagnostics Market:

Market Share (%) by Segment, 2022

Figure 6.4 The Alzheimer’s Diagnostics Market:

Market Share (%) by Segment, 2028

Figure 6.5 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), 2017-2028

Figure 6.6 Eli Lilly: Historical Revenue ($bn), 2012-2016

Figure 6.7 AmarantusBioScience: R&D Costs ($m), 2014-2015

Figure 6.8 Piramal Enterprise Historical Revenue by Business Unit 2015-2016

Figure 6.9 GE Healthcare Historical Revenues ($bn) 2014-2016

Figure 7.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2017

Figure 7.2 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2017-2022

Figure 7.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2022-2028

Figure 7.4 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2017-2028

Figure 7.5 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2022

Figure 7.6 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2028

Figure 7.7 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.8 The US Demographics: No. of People Aged 65 or Over, 2015 and 2030 Forecast

Figure 7.9 The European Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2017

Figure 7.10 The European Alzheimer’s Disease Therapeutics and

Diagnostics Market: Market Shares (%) by Leading Countries, 2017

Figure 7.11 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.12 The German Alzheimer’s Disease Therapeutics and Diagnostics MarkForecast: Revenue ($bn), 2017-2028

Figure 7.13 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.14The UK Alzheimer’s Disease Therapeutics and Diagnostics Market

Forecast: Revenue ($bn), 2017-2028

Figure 7.15The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.16 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.17 The Other European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.18 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.19 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.20 China’s Historical Healthcare Expenditure ($bn), 2001-2010

Figure 7.21 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.22 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.23 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 7.24 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2017-2028

Figure 8.1 The Global Over 65 Population: Forecast (millions), 2010-2050

Figure 8.2 Porter’s Five Force Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2016

Figure 10.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2017. 2022, 2028

Figure 10.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market ($bn) by Segment, 2017, 2022 and 2028